LWAC
ALNY icon

Laurel Wealth Advisors (California)’s Alnylam Pharmaceuticals ALNY Stock Holding History

Laurel Wealth Advisors (California)’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$261K Hold
1,100
– – 0.03% 546
2022
Q3 		$220K Buy
+1,100
New +$210K 0.02% 583
2021
Q4 		– Sell
-1,137
Closed -$215K – 764
2021
Q3 		$215K Buy
+1,137
New +$213K 0.04% 421

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Laurel Wealth Advisors (California)'s ALNY Position: Q4 2022 in Review

Laurel Wealth Advisors (California) held its Alnylam Pharmaceuticals (ALNY) position steady in Q4 2022 at 1,100 shares worth $261K. The position accounts for 0.03% of the portfolio, ranked #546.

Laurel Wealth Advisors (California) first reported a position in ALNY in Q3 2021 and has held it in 3 quarters since. 487 funds tracked by Wall St. Rank hold ALNY as of Q4 2022.

  • Laurel Wealth Advisors (California) held 1,100 shares of Alnylam Pharmaceuticals worth $261K as of Q4 2022.
  • Laurel Wealth Advisors (California) left its Alnylam Pharmaceuticals share count unchanged in Q4 2022.
  • Alnylam Pharmaceuticals made up 0.03% of Laurel Wealth Advisors (California)'s portfolio in Q4 2022, its #546 holding.
  • Laurel Wealth Advisors (California) first reported a position in Alnylam Pharmaceuticals in Q3 2021 and has held it in 3 quarters since.
  • 487 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2022.

Based on Laurel Wealth Advisors (California)'s 13F filing for Q4 2022, filed 14 Feb 2023.